Novan, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Novan, Inc. (NOVN) operates as a medical dermatology company focused on the development and commercialization of nitric oxide-based therapeutic products for skin diseases and viral infections in the United States; its core offerings include Wynzora (calcipotriene and betamethasone dipropionate cream for psoriasis), Rhofade (oxymetazoline hydrochloride cream for rosacea), Minolira (minocycline hydrochloride modified-release capsules for acne), and the investigational SB206 (berdazimer gel, 10.3%) topical prescription gel targeting molluscum contagiosum viral skin infections; the company leverages its proprietary Nitricil platform technology to deliver nitric oxide in solid form for localized antiviral and immunomodulatory effects. Founded in 2006 and headquartered in Durham, North Carolina, Novan primarily serves dermatology markets with prescription products promoted through its commercial portfolio of six branded drugs. In recent major developments, Novan filed for Chapter 11 bankruptcy protection in July 2023, leading to the September 2023 sale of substantially all assets—including berdazimer gel (now ZELSUVMI), the NITRICIL platform, and related programs—to Ligand Pharmaceuticals for $12.2 million net of debtor-in-possession financing; these assets now underpin Ligand's subsidiary Pelthos Therapeutics, launched in April 2024 to commercialize ZELSUVMI for molluscum contagiosum in adults and pediatric patients aged one year and older, with Pelthos combining with Channel Therapeutics in June 2025 to accelerate market entry.
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Novan to Report Full Year 2022 Financial Results on March 30, 2023
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q4 2021 Results - Earnings Call Transcript
Novan to Report Full Year 2021 Financial Results on February 22, 2022
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Novan Announces Strategic Priorities and Outlines Key Milestones